Dare Bioscience is a clinical‐stage biopharmaceutical company focused on developing and commercial products for women’s health. Incorporated in 2017 and headquartered in San Diego, California, the company leverages a combination of small molecules and drug‐device combination technologies to address unmet needs in reproductive health, contraception and hormone therapies. Dare Bioscience’s mission is to advance safe, effective and user‐friendly products that empower women with more control over their bodies and their health outcomes.
The company’s lead product candidate, Ovaprene®, is a hormone‐free monthly contraceptive vaginal ring designed to provide an alternative to daily oral pills, implants or intrauterine devices. In addition to Ovaprene, Dare is developing a suite of pipeline assets under the DARE-series platform, including DARE-HRT, a localized hormone replacement therapy for postmenopausal women, and DARE-LARC, which explores long-acting reversible contraception solutions. These programs are supported by a robust patent portfolio and a growing body of clinical data aimed at demonstrating safety, tolerability and ease of use.
Dare Bioscience serves the U.S. market through partnerships with contract research organizations, manufacturing firms and regulatory consultants. The company’s strategic collaborations extend to academic institutions and global development partners, enabling streamlined clinical trials and regulatory filings. By leveraging external expertise and flexible supply chain arrangements, Dare seeks to optimize development timelines and manage costs while maintaining rigorous quality and compliance standards.
The leadership team is headed by Steven Kelly, President and Chief Executive Officer, who brings over two decades of experience in specialty pharmaceuticals and women’s health. The executive management includes seasoned professionals in clinical development, regulatory affairs and commercial strategy. Guided by a board of directors with deep biotechnology and healthcare backgrounds, Dare Bioscience continues to advance its women-centric pipeline toward key clinical and regulatory milestones.
AI Generated. May Contain Errors.
Free DARE Stock Alerts